Emma Searle

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 483 citations · Full text

Hematological Malignancy, Magnetismm-3 Trial Results, Medicine +13

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Luciano Nicosia, Gary J. Spencer, Nigel Brooks et al. · Cancer Cell · 2023 · 97 citations · Full text

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong et al. · Blood · 2022 · 58 citations

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

Elias Jabbour, Emma Searle, Maher Abdul‐Hay et al. · Blood · 2023 · 42 citations

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Jeffrey Matous, Noa Biran, Aurore Perrot et al. · Blood · 2023 · 39 citations